See separate profiles for dexamethasone and lenalidomide.
- TRADE NAME: Ninlaro (Millennium)
- INDICATIONS: Multiple myeloma (in combination with lenalidomide and dexamethasone) in patients who have received at least one prior therapy
- CLASS: Proteasome inhibitor
- HALF-LIFE: 10 days
- FDA APPROVAL DATE: 11/20/2015
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Carbamazepine, Phenytoin, Rifampin, St John's Wort, Strong CYP3A inducers - PREGNANCY: Can cause fetal harm
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE links (above) to see two reviews of ixazomib in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 03/01/2024
